Abstract
This letter discusses the outcomes of a sequential cohort study of women with T1, N0, HER2-positive breast cancer with trastuzumab.
MeSH terms
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / enzymology*
-
Breast Neoplasms / pathology
-
Female
-
Humans
-
Lymph Nodes / pathology
-
Lymphatic Metastasis
-
Receptor, ErbB-2 / biosynthesis*
-
Trastuzumab
Substances
-
Antibodies, Monoclonal, Humanized
-
Receptor, ErbB-2
-
Trastuzumab